Blog
RSS FeedPosted by Michael Wonder on 27 Jul 2016
CADTH calls for patient input on submission from Pierre Fabre for Hemangiol (propranolol hydrochloride)
27 July 2016 - CADTH has received notice of a pending submission from Pierre Fabre for Hemangiol (propranolol hydrochloride). ...
Posted by Michael Wonder on 26 Jul 2016
CADTH recommends reimbursement of Sunvepra
20 July 2016 - CADTH has recommended that asunaprevir (Sunvepra) be reimbursed in Canada. ...
Posted by Michael Wonder on 25 Jul 2016
Praluent recommended for reimbursement by CADTH
20 July 2016 - CADTH has recommended that alirocumab (Praluent) be reimbursed in Canada. ...
Posted by Michael Wonder on 06 Jul 2016
Saskatchewan includes Lemtrada (alemtuzumab) on MS Drugs Program for eligible patients
5 July 2016 - Unique treatment delivered in only two cycles one year apart. ...
Posted by Michael Wonder on 22 Jun 2016
CADTH calls for feedback on drugs for the management of rheumatoid arthritis
22 June 2016 - A list of included studies on drugs for the management of rheumatoid arthritis is now available for ...
Posted by Michael Wonder on 11 Jun 2016
CADTH calls for patient input on submission from Teva for Fentora (fentanyl citrate)
10 June 2016 - CADTH calls for patient input on a submission from Teva Pharmaceuticals for Fentora (fentanyl citrate). ...
Posted by Michael Wonder on 08 Jun 2016
CADTH calls for patient input on submissions from Daiichi Sankyo for edoxaban tosylate
8 June 2016 - CADTH has received notice of pending submissions from Daiichi Sankyo for edoxaban tosylate. ...
Posted by Michael Wonder on 26 May 2016
CADTH Common Drug Review and pan-Canadian Oncology Drug Review engagement with the pan-Canadian Pharmaceutical Alliance
26 May 2016 - CADTH is engaging with the pan-Canadian Pharmaceutical Alliance office (pCPA), and effective immediately will be including the ...
Posted by Michael Wonder on 17 May 2016
Call for patient input on a submission from Boehringer Ingelheim for Praxbind
17 May 2016 - CADTH has received notice of a pending submission from Boehringer Ingelheim for Praxbind (idarucizumab) for the reversal ...
Posted by Michael Wonder on 17 May 2016
CADTH publishes final report for anti–vascular endothelial growth factor drugs for retinal conditions
17 May 2016 - The recommendations report is now available for the CADTH project on anti–vascular endothelial growth factor drugs for ...
Posted by Michael Wonder on 04 May 2016
Call for patient input on a submission from Teva Pharmaceuticals for reslizumab
4 May 2016 - CADTH has received notice of a pending submission from Teva Pharmaceuticals for reslizumab for use by patients ...
Posted by Michael Wonder on 02 May 2016
Call for patient input on a submission from Raptor Pharmaceutical for Quinsair (levofloxacin hemihydrate)
2 May 2016 - CADTH has received notice of a pending submission from Raptor Pharmaceutical for Quinsair (levofloxacin hemihydrate) oral solution ...
Posted by Michael Wonder on 26 Apr 2016
Call for patient input on a submission from Ferring Pharmaceuticals for budesonide
26 April 2016 - CADTH has received notice of a pending submission from Ferring Pharmaceuticals for budesonide for use by patients ...
Posted by Michael Wonder on 04 Apr 2016
CADTH calls for patient input on submissions from Boehringer Ingelheim & Servier
4 April 2016 - CADTH has received notice of pending submissions from Boehringer Ingelheim for empagliflozin with metformin hydrochloride (Synjardy) for ...
Posted by Michael Wonder on 30 Mar 2016
Call for patient input on a submission from Boehringer Ingelheim for Jardiance (empagliflozin)
30 March 2016 - CADTH has received notice of a pending submission from Boehringer Ingelheim for empagliflizin (Jardiance) for use by ...